Compare ARK Genomic Revolution ETF (ARKG) vs Freeport-McMoRan Inc (FCX) Price & Performance

ARK Genomic Revolution ETF (ARKG) trades at $44.69, up 0.31% with a bullish technical signal from moving averages but bearish oscillators. The ETF focuses on small- and mid-cap biotech stocks with 59% concentration in top 10 holdings. Recent news highlights ARKG's recovery from a 15% July correction, with biotech sector strength driven by FDA developments and M&A activity.

ARKG offers exposure to genomic innovation with improving valuations but faces sector volatility risks. The ETF's long-term EPS growth rate of 10.7% supports growth potential, though concentrated holdings and technical overbought signals warrant caution amid broader market sensitivity.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.